The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 49,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|09/16/14||Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease|
|IN.PACT Global Study Reports Favorable Outcomes in Real-World Patient Population and Validates Key Findings from IN.PACT SFA Trial WASHINGTON -- Sept. 16, 2014 -- Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic, Inc. (NYSE: MDT) augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for p... |
|09/16/14||People with Type 2 Diabetes Achieve Greater Satisfaction with Insulin Pumps vs. Multiple Daily Injections|
|New Data from the OpT2mise Efficacy Studyto be Presented at EASD Annual Meeting VIENNA - September 16, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that new results from the OpT2mise trial are being presented at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting. OpT2mise is the largest global study to compare insulin pump therapy to multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Three new poster presentations at EAS... |
|09/15/14||Medtronic Launches SEEQ(TM) Wearable Cardiac Monitoring System in United States|
|New External Heart Monitor and Remote Monitoring Center Help Patients Find Answers to Unexplained Cardiac Symptoms MINNEAPOLIS - September 15, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. launch of the SEEQ(TM) Mobile Cardiac Telemetry (MCT) System, an external, wire-free, adhesive heart monitor that can be worn for up to 30 days to help detect and diagnose the cause of irregular heartbeats in patients. Medtronic completed the acquisition of U.S.-based Corventis, Inc., which deve... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|